NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Bliss GVS Pharma Recommends 100% Final Dividend of Rs 1 per Share for FY 2025-26
Bliss GVS Pharma has approved its audited financial results for the fiscal year ended March 31, 2026, and recommended a final dividend of Rs 1 per share (100% of face value). The company's auditors provided an unmodified opinion on both standalone and consolidated financial statements, indicating no major accounting discrepancies. Additionally, BDO India Services has been re-appointed as the internal auditor for the upcoming fiscal year. The Annual General Meeting is scheduled for July 15, 2026, to finalize these approvals.
முக்கிய அம்சங்கள்
Recommended a final dividend of 100%, which is Rs 1 per equity share of face value Rs 1.Audited standalone and consolidated financial results for FY 2025-26 approved with an unmodified audit opinion.Re-appointment of M/s. BDO India Services Private Limited as Internal Auditor for FY 2026-27.41st Annual General Meeting scheduled for July 15, 2026, via video conferencing.Consolidated results now include new subsidiaries in Kenya and the Democratic Republic of the Congo.
👀 கவனிக்க வேண்டியவை
Investors should track the record date for the Rs 1 dividend payout and review the full earnings report to assess the growth of the new African subsidiaries. The 100% dividend recommendation reflects management's confidence in the company's cash flow.
Bliss GVS Pharma Assigned [ICRA]A- (Stable) Rating for Rs 100 Crore Bank Facilities
ICRA Limited has assigned new credit ratings to Bliss GVS Pharma Limited for its bank facilities totaling Rs 100.00 crore. The long-term rating is established at [ICRA]A- with a Stable outlook, while the short-term rating is assigned as [ICRA]A2+. These ratings apply to fund-based and non-fund-based limits specifically associated with Federal Bank. This independent assessment reflects the company's creditworthiness and provides a benchmark for its financial stability.
முக்கிய அம்சங்கள்
Assigned [ICRA]A- (Stable) long-term rating for Rs 100.00 crore bank facilitiesAssigned [ICRA]A2+ short-term rating for fund-based and non-fund-based limitsThe rating action covers facilities specifically held with Federal Bank LimitedThe 'Stable' outlook indicates ICRA's expectation of a steady credit profile in the medium term
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive validation of the company's financial health and debt-servicing capability. This investment-grade rating provides a baseline for monitoring the company's future financial risk and borrowing costs.
Bliss GVS Pharma Appoints Two Independent Directors with 35+ Years Experience
Bliss GVS Pharma has appointed Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah as Additional Independent Directors for a five-year term starting April 3, 2026. Mr. Mahadevan brings over 35 years of global finance leadership from major pharmaceutical firms such as Novartis and Sandoz. Mr. Shah is a veteran Chartered Accountant with over 36 years of experience in taxation and audit, currently serving on boards like Siyaram Silk Mills. These appointments are intended to strengthen the board's strategic oversight and financial governance, subject to shareholder approval via postal ballot.
முக்கிய அம்சங்கள்
Appointment of two Independent Directors for a 5-year term from April 3, 2026, to April 2, 2031Mr. Vijayanarayanan Mahadevan brings 35+ years of experience in global finance and pharma manufacturingMr. Deepak Rameshchandra Shah brings 36+ years of expertise in taxation, audit, and corporate leadershipBoard has approved the draft Postal Ballot Notice to seek shareholder approval for these appointments
👀 கவனிக்க வேண்டியவை
Investors should view these appointments as a positive move to enhance board-level expertise and corporate governance. No immediate action is required as these are routine but high-quality leadership additions.
Bliss GVS Pharma Announces TDS Guidelines for Re. 0.50 Interim Dividend; Record Date Feb 18
Bliss GVS Pharma has declared an interim dividend of Re. 0.50 per equity share for the financial year 2025-2026. The company has established February 18, 2026, as the record date to identify eligible shareholders for this payout. This communication outlines the Tax Deduction at Source (TDS) procedures, where a 10% tax will be deducted for resident shareholders with a valid PAN. Shareholders must submit necessary tax exemption forms like 15G/15H by February 23, 2026, to avoid higher tax withholding.
முக்கிய அம்சங்கள்
Interim dividend of Re. 0.50 per equity share (50% of face value) declared for FY 2025-26.Record date for dividend eligibility is fixed as Wednesday, February 18, 2026.TDS of 10% applies to resident shareholders with PAN; 20% applies if PAN is invalid or not linked to Aadhaar.No TDS for resident individuals if the total dividend received during FY 2025-26 does not exceed Rs. 10,000.Deadline for submitting tax-related documents (Form 15G/15H/TRC) is Monday, February 23, 2026.
👀 கவனிக்க வேண்டியவை
Shareholders should ensure their PAN and Aadhaar are linked and bank details are updated in their demat accounts to receive the dividend smoothly. If eligible for tax exemption, submit Form 15G/15H to the company's registrar by the February 23 deadline.
Bliss GVS Pharma Clarifies Speculative News Regarding Stake Sale to Anupam Rasayan
Bliss GVS Pharma has officially addressed a news report from CNBC Awaaz dated February 13, 2026, which suggested that Anupam Rasayan might acquire a stake in the company. The company clarified that this news is speculative and did not originate from any official communication. As of the current date, no arrangement or decision regarding a stake sale has been finalized or approved by the promoters. The disclosure was made under Regulation 30(11) to prevent the establishment of false market sentiment.
முக்கிய அம்சங்கள்
Company denies CNBC Awaaz report titled 'Bliss GVS में हिस्सा ले सकती है अनुपम रसायन' as speculative.Management confirms no decision or arrangement has been crystallized or approved by promoters as of Feb 13, 2026.Clarification issued under SEBI Regulation 30(11) to maintain market integrity.Investors advised to rely only on official exchange filings rather than media reports.
👀 கவனிக்க வேண்டியவை
Investors should remain cautious and avoid reacting to unverified media reports, as the company has officially denied any finalized deal. Monitor the stock for volatility but prioritize official regulatory filings for investment decisions.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Bliss GVS Pharma: Two Whole-Time Directors Resign Effective February 10, 2026
Bliss GVS Pharma Limited has announced the resignation of two Whole-Time Directors, Mrs. Shruti Vishal Rao and Dr. Vibha Gagan Sharma, effective February 10, 2026. Both directors are daughters of the current Managing Director and CEO, Mr. Narsimha Shibroor Kamath, and cited other professional commitments as the reason for their departure. The Board accepted these resignations in a meeting held at shorter notice on the same day. This simultaneous exit of two family-member directors from the board marks a significant change in the company's executive leadership structure.
முக்கிய அம்சங்கள்
Resignation of Mrs. Shruti Vishal Rao and Dr. Vibha Gagan Sharma as Whole-Time Directors effective Feb 10, 2026.Both outgoing directors are daughters of the Managing Director & CEO, Mr. Narsimha Shibroor Kamath.The resignations were attributed to other professional commitments by the directors.The Board meeting to accept the resignations was held at shorter notice on February 10, 2026, between 5:30 PM and 6:00 PM.Both individuals will also cease to be members of all company committees effective immediately.
👀 கவனிக்க வேண்டியவை
Investors should monitor for any new board appointments to understand if the company is moving towards more professional management or if other family members will be inducted. The simultaneous exit of two promoter-related directors warrants a watch on the company's future succession and governance strategy.
Bliss GVS Pharma Declares 50% Interim Dividend; Sets Feb 18 as Record Date
Bliss GVS Pharma Limited has announced an interim dividend of ₹0.50 per equity share for the financial year 2025-2026. This payout represents 50% of the face value of ₹1 per share. The company has officially fixed Wednesday, February 18, 2026, as the record date to determine shareholder eligibility. The dividend is expected to be disbursed to eligible shareholders within 30 days of its declaration on February 10, 2026.
முக்கிய அம்சங்கள்
Interim dividend of ₹0.50 per equity share (50% of face value ₹1) declaredRecord date for dividend eligibility fixed as February 18, 2026Dividend declared for the Financial Year 2025-2026Payment to be completed within 30 days from the declaration date of February 10, 2026
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the shares before the ex-dividend date to be eligible for the ₹0.50 per share payout. This announcement reflects a positive cash return to shareholders for the current fiscal year.
Bliss GVS Shareholders Approve Narsimha Kamath as Managing Director with 99.9% Majority
Bliss GVS Pharma Limited has announced the successful passage of a special resolution to appoint Mr. Narsimha Shibroor Kamath as Managing Director. The resolution was passed via postal ballot with an overwhelming majority of 99.90% of the votes cast in favour. A total of 6.37 crore votes were polled, representing approximately 60.21% of the total shareholding. The promoter group and public institutions showed unanimous support for the appointment, indicating strong internal and institutional alignment.
முக்கிய அம்சங்கள்
Special resolution passed for the appointment of Mr. Narsimha Shibroor Kamath as Managing DirectorTotal votes polled reached 6,36,93,053, representing 60.21% of the total 10.58 crore sharesThe appointment received 99.90% approval (6,36,26,720 votes) from participating shareholdersPromoter group and Public Institutions voted 100% in favour of the resolutionOnly 0.10% of votes (66,333) were cast against the proposal
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive sign of leadership continuity and strong shareholder backing. No immediate action is required, but monitoring the new MD's strategic direction for the company is advised.
Bliss GVS Pharma Proposes Appointment of Narsimha Shibroor Kamath as Managing Director
Bliss GVS Pharma has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Narsimha Shibroor Kamath as Managing Director for a three-year term. Mr. Kamath, who currently serves as the Chief Executive Officer, will be redesignated as Managing Director & CEO upon approval. As he is 72 years old, the company is seeking a special resolution to confirm that his continued leadership is in the best interest of the firm. The e-voting process for shareholders will run from December 31, 2025, to January 29, 2026.
முக்கிய அம்சங்கள்
Proposed appointment of current CEO Mr. Narsimha Shibroor Kamath as Managing Director for a 3-year tenure.Special resolution required due to the appointee's age of 72 years as per Companies Act requirements.E-voting period scheduled from December 31, 2025, to January 29, 2026, with results by February 2, 2026.The appointee will hold the dual designation of Managing Director & Chief Executive Officer.The board has appointed Mr. Vijay Yadav of AVS & Associates as the scrutinizer for the voting process.
👀 கவனிக்க வேண்டியவை
Investors should monitor the voting results to ensure leadership continuity and review the detailed explanatory statement for specifics on the proposed remuneration package.
Bliss GVS Pharma Appoints Promoter S.N. Kamath as MD & CEO for 3-Year Term
The Board of Bliss GVS Pharma has approved the appointment of Mr. S. N. Kamath as Managing Director and CEO for a three-year term, subject to shareholder approval. Mr. Kamath, who is currently the CEO and a promoter, has been instrumental in expanding the company's global footprint to over 60 countries. The transition formalizes his leadership role as the company seeks to maintain its strategic growth trajectory. The appointment will be finalized following a Special Resolution passed via Postal Ballot.
முக்கிய அம்சங்கள்
Appointment of Mr. S. N. Kamath as Managing Director for a 3-year consecutive term.Mr. Kamath is the company promoter and has been serving as the Chief Executive Officer.Under his leadership, the company has established a presence in more than 60 countries.The appointment is subject to shareholder approval through a Special Resolution via Postal Ballot.Mr. Kamath is the father of two existing Whole-Time Directors, ensuring family-led management continuity.
👀 கவனிக்க வேண்டியவை
This move signals leadership stability and continued promoter commitment to the company's operations. Investors should monitor the Postal Ballot results and look for any new strategic initiatives under his formal MD tenure.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
